BRISTOL-MYERS SQUIBB COMPANY |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 44.01 USD | -0.23% |
|
-2.07% | -14.23% |
| May. 16 | Everlasting momentum |  |
| May. 16 | Bristol Myers Gets FDA OK of Breyanzi in Follicular Lymphoma | DJ |
ETFs positioned on Bristol-Myers Squibb Company
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 12.97% | 254 M€ | +10.97% | - | |
| 4.99% | 2 M€ | -.--% | ||
| 4.01% | 17 M€ | +7.73% | - | |
| 2.63% | 23 M€ | +13.93% | - | |
| 2.37% | 2 M€ | -25.75% | ||
| 2.29% | 31 M€ | +2.10% | - | |
| 2.08% | 9 M€ | -.--% | - | |
| 1.90% | 16 M€ | -3.37% | ||
| 1.85% | 2 M€ | +10.27% | ||
| 1.43% | 5 M€ | -72.95% | - | |
| 1.42% | 9 M€ | -4.31% | - | |
| 1.37% | 26 M€ | +16.85% | - | |
| 1.26% | 800 M€ | +6.86% | ||
| 1.00% | 85 M€ | +1.65% | ||
| 0.99% | 9 M€ | +10.44% | ||
| 0.83% | 104 M€ | +10.57% | ||
| 0.82% | 8 M€ | +5.66% | ||
| 0.80% | 2,383 M€ | +13.60% | ||
| 0.78% | 3 M€ | +15.16% | - | |
| 0.78% | 13 M€ | -.--% | - |
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques.
The United States account for 70.1% of net sales.
Sector
Pharmaceuticals
Calendar
2024-07-26
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
44.03
USD
Average target price
53.19
USD
Spread / Average Target
+20.81%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -14.23% | 89.25B | |
| +32.09% | 693B | |
| +29.39% | 584B | |
| -1.34% | 372B | |
| +20.34% | 332B | |
| +7.39% | 294B | |
| +14.25% | 239B | |
| -3.03% | 211B | |
| +10.02% | 210B | |
| +8.49% | 168B |
- Stock Market
- Equities
- BMY Stock
- Funds and ETFs Bristol-Myers Squibb Company
